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Regulatory effects of histamine and histamine receptor
expression in human allergic immune responses
Abstract
Histamine influences several immune/inflammatory and effector functions in addition to its dominant
role in type I hypersensitivity reactions. Histamine can selectively recruit the major effector cells into
tissue sites and affect their maturation, activation, polarization, and other functions leading to chronic
inflammation. Histamine also regulates monocytes, dendritic cells, T cells and B cells, as well as related
antibody isotype responses. The diverse effects of histamine on immune regulation appear to be due to
differential expression and regulation of four types of histamine receptors and their distinct intracellular
signals. In addition, differences in affinities of these receptors for histamine are highly decisive for the
biological effects of histamine and drugs that target histamine receptors.
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Abstract 
Histamine influences several immune/inflammatory and effector functions in 
addition to its dominant role in type I hypersensitivity reactions. Histamine can 
selectively recruit the major effector cells into tissue sites and affect their 
maturation, activation, polarization, and other functions leading to chronic 
inflammation. Histamine also regulates monocytes, dendritic cells, T cells and B 
cells, as well as related antibody isotype responses. The diverse effects of 
histamine on immune regulation appear to be due to differential expression and 
regulation of 4 types of histamine receptors and their distinct intracellular signals. In 
addition, differences in affinities of these receptors for histamine is highly decisive 
for the biological effects of histamine and drugs that target histamine receptors.  
 
Molecular Basis for Action 
Histamine (2-[4-imidazole]-ethylamine) is a low-molecular-weight amine 
synthesized from L-histidine exclusively by histidine decarboxylase. It is produced by 
various cells throughout the body, including central nervous system neurons, gastric 
mucosa parietal cells, mast cells, basophils and lymphocytes (1-4). Since its 
discovery as an uterine stimulant more than 100 years ago it has become one of the 
most intensely studied molecules in medicine. The name histamine was given after 
the Greek word for tissue, histos after it was isolated first from liver and lung tissue 
and than from several other sites. Its smooth muscle stimulating and vasodepressor 
action was demonstrated in the first experiments by Dale and Laidlaw (5), who also 
found that the effects of histamine mimicked those occurring during anaphylaxis. 
Histamine is involved in the regulation of many physiological functions including 
cell proliferation and differentiation, hematopoiesis, embryonic development, 
regeneration, and wound healing. Within central nervous system it affects cognition 
and memory, the regulation of cycle of sleeping and waking, energy and endocrine 
homeostasis (6). In human pathology histamine triggers acute symptoms due to its 
very rapid activity on vascular endothelium and bronchial and smooth muscle cells 
leading to the development of such symptoms as acute rhinitis, bronchospasm, 
cramping, diarrhea or cutaneous wheal and flare responses. In addition to these 
effects on the immediate type response histamine significantly regulates the immune 
response and a number of chronic phase inflammatory events (1, 2). For example, 
histamine is increased in bronchoalveolar lavage fluid from patients with allergic 
asthma and this increase negatively correlates with airway function (7). An increase 
in histamine levels has been noted in the skin and plasma of patients with atopic 
dermatitis (8) and in chronic urticaria (9). Histamine levels are also increased in 
multiple sclerosis (10) and in psoriatic skin (11). Both plasma and synovial fluid of 
patients with rheumatoid arthritis and plasma of patients with psoriatic arthritis have 
increased histamine levels (12).  Consequently the antihistamines should be viewed 
as systemic anti-allergic agents and immunoregulators.  
 
Histamine receptors 
The pleiotropic effects of histamine are triggered by activating on one or several 
of histamine membrane receptors on different cells. Four subtypes of receptors 
(histamine receptor (HR) 1, HR2, HR3, and HR4) have been described (Table 1). All 
of these receptors belong to the G-protein-coupled receptor family. They are 
heptahelical transmembrane molecules that transduce extracellular signal by using 
G-proteins and intracellular second messenger systems (1, 2). The active and 
inactive states of HRs exist in equilibrium. However, it has been shown in 
recombinant systems that HRs can trigger downstream events in the absence of 
receptor occupancy by an agonist, which accounts for constitutive spontaneous 
receptor activity (13).  
HRs agonists stimulate the active state in the receptor and inverse agonists, the 
inactive one. An agonist with a preferential affinity for the active state of the receptor 
stabilizes the receptor in its active conformation leading to continuous activation 
signal. An inverse agonist with a preferential affinity for the inactive state stabilizes 
the receptor in this conformation and consequently induces an inactive state, which is 
characterized by blocked signal transduction via the HR (13). In reporter gene 
assays, constitutive HR1-mediated nuclear factor (NF)-κB activation has been shown 
to be inhibited by many of the clinically used H1-antihistamines, indicating that these 
agents are inverse HR1-agonists (13). Constitutive activity has now been shown for 
all four histamine receptors(13).  
Specific activation or blockade of HRs showed that they differ in expression, 
signal transduction or function and improved the understanding of the role of 
histamine in physiology and disease mechanisms. It has long been recognized that 
most positive effects of histamine are mediated by HR1, while HR2 is mostly involved 
in its suppressive activities. The human Gq/11-coupled HR1 is encoded by a single 
exon gene located on the distal short arm of chromosome 3p25b and contains 487 
aminoacids. The HR1 is expressed in numerous cells including airway and vascular 
smooth muscle cells, hepatocytes, chondrocytes, nerve cells, endothelial cells, 
dendritic cells, monocytes, neutrophils, T and B cells (1, 2). Histamine binds to 
transmambrane domains 3 and 5. Activation of the HR1-coupled Gq/11 stimulates the 
inositol phospholipid signaling pathways resulting in formation of inositol-1,4,5-
triphosphate (IP3) and diacylglycerol and an increase in intracellular calcium (14). 
The rise in intracellular calcium accounts for nitric oxide production, liberation of 
arachidonic acid from phospholipids increased cyclic AMP. The HR1 also activates 
phospholipase D and phospholipase A2 and the transcription factor NF-κB. through 
Gq/11 and Gβγ upon agonist binding. Constitutive activation of NF-κB occurs only 
through Gβγ (14). The HR1 is responsible for the development of many symptoms of 
allergic disease. Targeted disruption of the H1-receptor gene in mice results in the 
impairment of neurologic functions such as memory, learning, locomotion, and 
nocioperception, and in aggressive behavior. Immunologic abnormalities have also 
been described in HR1-deleted mice, with impairment of both T and B cell responses 
(15). Activation of HR1 is responsible for many symptoms of allergic disease.  
In humans the intronless gene encoding HR2 is located on chromosome 5. The 
human HR2 is a protein of 359 aminoacids coupled to both adenylate cyclase and 
phosphoinositide second messenger systems by separate GTP-dependent 
mechanisms including Gαs and also induces activation of c-Fos, c-Jun PKC and 
p70S6 kinase (16). Studies in different species and several human cells 
demonstrated that inhibition of characteristic features of the cells by primarily cAMP 
formation dominates in HR2-dependent effects of histamine.  
Human HR3 encoded by a gene, which consists of four exons on chromosome 
20 has been demonstrated in 1987 and cloned recently (17). HR3 has initially been 
identified in the central and peripheral nervous system as pre-synaptic receptors 
controlling the release of histamine and other neurotransmitters (dopamine, 
serotonine, noradrenaline, GABA, and acetylocholine). HR3 signal transduction 
involves Gi/o of G proteins leading to inhibition of cAMP and accumulation of Ca
++ and 
activation of mitogen-activated protein kinase (MAPK) pathway. R-α-methyhistamine 
and imetit are agonists, thioperamide and clobenpropit are antagonists of HR3. The 
control of mast cells by histamine acting on HR3 involves neuropeptide-containing 
nerves and might be related to a local neuron-mast cell feedback loop controlling 
neurogenic inflammation. Dysregulation of this feedback loop may lead to excessive 
inflammatory responses and suggests a novel therapeutic approach by using HR3 
agonists. Probably more than one HR3 subtype exists, which differ in central nervous 
system localization and signaling pathways.  
Human HR4, which is encoded by a gene containing three exons, separated by 
two large introns located in chromosome 18q11.2. It has 37-43% homology to HR3 
(58% in the transmembrane region). HR4 is functionally coupled to G protein Gi/o, 
inhibiting forskolin-induced cAMP formation like the HR3 [14]. HR4 shows high 
expression in the bone marrow and peripheral hematopoietic cells, neutrophils, 
eosinophils and T cells, basophils and mast cells and moderate expression in spleen, 
thymus, lung, small intestine, colon, and heart (18). Until now relatively little is known 
about the biological function of HR4. It seems to be involved in the immune 
regulatory functions including chemotaxis and cytokine secretion (1, 2). H4 histamine 
receptor is expressed in cells of the innate immune system, which include NK cells, 
monocytes, and dendritic cells (19). 
HRs form dimers and even oligomers, which allow cooperation between HRs 
and other G protein-coupled receptors. Thus, the effects of histamine upon receptor 
stimulation can be very complex. 
 
Synthesis and metabolism of histamine 
The classical cellular sources of histamine are mast cells and basophils, gastric 
enterochromaffin-like cells, platelets and histaminergic neurons. Interestingly the cells 
in the immune system, which do not store histamine show high HDC activity and are 
capable of production of high amounts of histamine, which is secreted immediately 
after synthesis (20). These cells include platelets, monocytes/macrophages, dendritic 
cells, neutrophils, T and B lymphocytes.  
Histamine is synthesized by decarboxylation of histidine by L-histidine 
decarboxylase (HDC), which is dependent on the cofactor pyridoxal-5´-phosphate 
(21). Mast cells and basophils are the major source of granule-stored histamine, 
where it is closely associated with the anionic proteoglycans and chondroitin-4-
sulfate. Histamine is released when these cells degranulate in response to various 
immunologic and nonimmunologic stimuli. In addition, several myeloid and lymphoid 
cell types (dendritic cells [DCs] and T cells), which do not store histamine, show high 
HDC activity and are capable of production of high amounts of histamine (20). HDC 
activity is modulated by cytokines, such as IL-1, IL-3, IL-12, IL-18, GM-CSF, 
macrophage-colony stimulating factor, TNF-α and calcium ionophore, in vitro (22). 
HDC activity has been demonstrated in vivo in conditions such as LPS stimulation, 
infection, inflammation, and graft rejection (14).  The generation of HDC-deficient 
mice provided histamine-free systems to study the role of endogenous histamine in a 
broad range of normal and disease processes. These mice show decreased numbers 
of mast cells and significantly reduced granule content, which suggests that 
histamine might affect the synthesis of mast cell granule proteins (23). IgE binding to 
the FcεRI on IL-3-dependent mouse bone marrow-derived mast cells induces the 
expression of HDC through a signaling pathway distinct to that operating during 
antigen-stimulated FcεRI activation (24). More than 97% of the histamine is 
metabolized in 2 major pathways before excretion (25). Histamine N-
methyltransferase metabolizes the majority of histamine to N-methylhistamine, which 
is further metabolized to the primary urinary metabolite M-methylimidazole acetic acid 
by monoamine oxidase. Diamine oxidase metabolizes 15% to 30% of histamine to 
imidazole acetic acid.  
 
Histamine in chronic inflammatory responses 
Chronic inflammatory response is one of the hallmarks of allergic diseases. 
Over the course of pollen season, there might be even a 10-fold increase in numbers 
of nasal epithelial submucosal mast cells. Histamine released from these cells might 
not only induce acute allergic symptoms but also be crucial for sustaining this 
response into a chronic phase as increasing evidence suggests that it influences 
several immune/inflammatory and effector functions (Table 2) (2).  
Histamine contributes to the progression of allergic-inflammatory responses by 
enhancement of the secretion of proinflammatory cytokines like IL-1α, IL-1β, IL-6 as 
well as chemokines like RANTES or IL-8, both in several cell types and local tissues 
(26-29). Endothelial cells express functional HR1 and HR2  and increased adhesion 
molecule expression such as ICAM-1, VCAM-1 and P-selectin was demonstrated by 
histamine infusion via HR1 (30-32). Histamine regulates the expression of its own 
receptors on endothelial cells and influences the overall inflammatory reaction (33).  
Histamine regulates granulocyte accumulation to tissues in distinct ways. 
Allergen-induced accumulation of eosinophils in the skin, nose and airways is 
potently inhibited by H1-antihistamines (34). The effect of histamine on eosinophil 
migration may differ according to the dose. Whereas high doses inhibit eosinophil 
chemotaxis via HR2, low doses enhance eosinophil chemotaxis via HR1 (35). 
Recently, it has been shown that the histamine receptor responsible for the 
selective recruitment of eosinophils, is HR4 (36). Histamine possesses all the 
properties of a classical leukocyte chemoattractant (i.e., agonist-induced actin 
polymerization, mobilization of intracellular calcium, alteration in cell shape, and 
upregulation of adhesion molecule expression). The eosinophils chemoattractive 
ability of histamine is weak, when compared to the potent CCR3-binding 
chemokines, eotaxin and eotaxin-2 (36-39). Histamine possesses all the properties 
of a classical leukocyte chemoattractant, including: agonist-induced actin 
polymerization, mobilization of intracellular calcium, alteration in cell shape, and up-
regulation of adhesion molecule expression. In vivo, allergen-specific wild-type, but 
not histamine H1 receptor-deficient CD4+ T cells were recruited to the lungs of naive 
recipients following inhaled allergen challenge (40). Histamine inhibits neutrophil 
chemotaxis due to histamine H2 receptor-triggering, which is mimicked by 
impromidine (histamine H2 receptor agonist), but not by betahistine (histamine H1 
receptor agonist) (41). Histamine contributes to the progression of allergic-
inflammatory responses by enhancement of the secretion of proinflammatory 
cytokines such as IL (interleukin)-1α, IL-1β, IL-6 as well as chemokines such as 
RANTES or IL-8, in several cell types and local tissues (27, 28, 42, 43). Histamine 
induces the CC chemokines, monocyte chemotactic protein 1 and 3, RANTES, and 
eotaxin in explant cultures of human nasal mucosa via histamine H1 receptor, 
suggesting a prolonged inflammatory cycle in allergic rhinitis between the cells that 
release histamine and their enhanced migration to nasal mucosa (44).  
However, histamine upon activation of the HR4 induces enhanced migration of 
eosinophils towards eotaxin and eotaxin-2 (45) . On the other hand, the potential of 
histamine alone to act as an eosinophil chemoattractant in vivo, might be augmented 
by other factors, such as growth factors or cytokines like IL-5, the cytokine specific for 
the differentiation, activation, and survival of eosinophils (46). Triggering of HR4 also 
induces chemotaxis of mast cells (47). Experiments in mice showed that mast cells 
from wild type and HR3- receptor-deleted mice migrated in response to histamine, 
while mast cells from the HR4-deleted mice did not. Thus, chemotaxis of eosinophils 
and mast cells via histamine is triggered mainly through the HR4. The HR4-mediated 
chronic inflammatory effects of histamine may be aborted by administration of HR4 
antagonists and combination therapies with the HR1antagonists are a promising 
approach.  
Histamine inhibits  neutrophil chemotaxis due to HR2 triggering, which is 
mimicked by impromidine (HR2 agonist), but not by betahistine (HR1 agonist). In 
addition, histamine inhibits neutrophil activation, superoxide formation and 
degranulation via HR2 (48). Down regulation of NF-κB, which acts as a potent 
transcription factor in initiating inflammation may represent a possible mechanism for 
H1-antihistamines to inhibit inflammatory cell accumulation (49). Low concentrations 
of H1-antihistamines, cetirizine and azelastine have been demonstrated to down-
regulate NF-κB expression in parallel to inhibition of pro-inflammatory cytokines (50). 
A recent study with HDC-deficient and mast cell-deficient mice demonstrated that 
histamine mainly derived from non-mast cells plays an essential role in angiogenesis 
and the generation of inflammatory granulation (51). The pretreatment of the nasal 
mucosa and the conjunctivae with topical H 1-antihistamineshas been shown to 
down-regulate the inflammation locally after an allergen challenge (52). Decreased 
macrophage IL-6 production and in dendritic cells decreased expression of CD86 
and decreased IL-8 production was shown (53, 54). 
These findings open a new therapeutic window for  antihistamines as systemic 
antiallergic agents.  Although the use of H1-antihistamine in persistent asthma is 
currently not recommended some recent evidence might finally lead to reevaluation 
of this approach. Histamine has been found in the airways of asthma patients even 
during asymptomatic periods (55, 56). Increased number of degranulated mast cells 
and basophils has been detected in biopsies of asthmatic airways long after an acute 
asthma attack (57). The level of histamine in bronchoalveolar lavage fluid (BALF) has 
been found to correlate with the severity of asthma and  airway hyperresponsiveness 
(58).  
Inhaled and intravenous histamine causes bronchoconstriction as one of the 
first recognized properties of histamine, which is inhibited by H1-antihistamines. As a 
manifestation of airway hyper-responsiveness, asthmatic individuals are more 
sensitive to the bronchoconstrictor effect of histamine than normal individuals. In 
addition in vitro studies have shown increased histamine release in basophils and 
mast cells obtained from asthmatic subjects compared with cells obtained from 
persons without asthma (55). In lavage fluid of the patients treated with H1-
antihistamines decreased levels of proinflammatory cytokines, and mediators (e.g., 
histamine, leukotrienes, prostaglandin, cell adhesion molecules (e.g., intercellular 
adhesion molecules and vascular cell adhesion molecules), cells (e.g., eosinophils 
and neutrophils), plasma exudation along with reduced symptom score has been 
found (59). 
The potential efficacy of H1 antihistamines in asthma has been intensively 
investigated (59). It has been shown that inhalation, intravenious or oral 
administration of clemastine or chlorpheniramine induced significant 
bronchodilatation. However, second generation H1-antihistamines induce only a very 
limited increase of FEV1 (5-10 % over baseline) by recommended doses (60, 61). 
There is variable effect on allergen challenge or exercise-induced bronchospasm. 
Only terfenadine with 3 times recommended dose inhibited early and late 
bronchoconstrictor response (61). Terfenadine, cetirizine and loratadine with 2 to 5 
times the usual dose appeared to improve asthma symptoms in mild seasonal or 
perennial asthma, but did not block development of bronchial hyperresponsiveness in 
seasonal pollen asthma nor show apparent benefit in patients with more severe 
asthma (60, 61). In patients with concurrent symptoms of allergic rhinitis and asthma, 
treatment with H1-antihistamine results in significant decrease in symptoms of both 
rhinitis and asthma, decrease in use of β2-agonists, and some improvement of 
airway function (62). Montelukast sodium – a leukotriene receptor antagonist showed 
similar effect as desloratadine (62).  
The mechanisms of the beneficial effect of HR1-antihistamines in asthma have 
been investigated in a mice model. Fexofenadine was found to suppress allergic 
immune/inflammatory responses in sensitised mice (63). Treatment with 
fexofenadine diminished Th2-like response that typically follows sensitisation and 
challenge with allergen. Decreased secretion of IL-4, IL-5, prevention of allergen-
specific IgE increase and reduced eosinophilia in lung tissue and BALF as well as 
normalization of airway response to metacholine was observed.  
Importantly, in an adoptive transfer model it was demonstrated that the target 
mechanism was T cell-mediated. Lung T cells from sensitised mice when transferred 
to naïve recipient mice triggered airway hyperresponsiveness and allergic 
inflammatory features after allergen challenge. In contrast naïve mice which received 
T cells from sensitised mice treated before with fexofenadine showed no such 
responses to allergen challenge (63). The inability of T cells from HR1 antihistamine-
treated allergen-sensitised mice to transfer allergic sensitivity to naïve recipients 
resulted from an alteration in the cytokine production profile of the transferred cells.  
Consistently, histamine-induced concentration-dependent release of IL-6 and β-
glucuronidase from macrophages isolated from the human lung parenchyma was 
inhibited by fexofenadine but not by ranitidine, an H2-receptor antagonist (64). Thus 
long-term treatment with H1 antihistamines can alter disease progression in patients 
with respiratory allergy associated with tissue damage/remodeling mediated by 
macrophage and Th2 cell activation. It has been shown that treatment with cetirizine 
over period of 18 months delayed the onset of asthma in some young children with 
atopic dermatitis (65). Although H1-antihistamines clearly show weaker 
antiinflammatory effects than corticosteroids but they may in a subtle way modulate 
the immune response by modulating the balance between Th1, Th2 and Treg cells 
and suppressing the accumulation of inflammatory cells.  Although previous studies 
suggested a basal tone of smooth muscle mediated by histamine binding to HR1, 
currently constitutive intrinsic activity of the HR1 without any occupation by histamine 
could be more relevant. Histamine also induces proliferation of cultured airway 
smooth muscle cells (66).  
Difference in histamine response between species has been reported indicating 
a role for HR2-mediated bronchodilatation in cat, rat, rabbit, sheep and horse (67). 
However, in humans, H2-antihistamines such as cimetidine and ranitidine do not 
cause bronchoconstriction in normal or asthmatic individuals (68). Although there is 
no direct evidence that it plays a role in disease pathogenesis, HR2-mediated gastric 
secretion is impaired in asthma (69). Histamine may play an important role in the 
modulation of the cytokine network in the lung via HR2, HR3 and HR4 that are 
expressed in distinct cells and cell subsets. Apparently, due to the same signal 
transduction patterns, β2 adrenergic receptors may function similar to HR2 in 
humans. The role of histamine and other redundant G-protein-coupled receptors in 
the regulation of immune/inflammatory pathways in the lung remain to be intensely 
focused in future studies. 
 
Role of histamine in the regulation of immune response  
Antigen-presenting cells 
Dendritic cells (DC) are often located in the vicinity of various histamine sources 
such as connective tissue mast cells. They are potent antigen-presenting and 
cytokine-producing cells. Therefore, histamine may effectively influence the immune 
response through DC. These professional antigen-presenting cells mature from 
monocytic and lymphoid precursors and acquire DC1 and DC2 phenotypes, which in 
turn facilitate the development of Th1 and Th2 cells, respectively. Endogenous 
histamine is actively synthesized during cytokine-induced DC differentiation, which 
acts in autocrine and paracrine fashion and modifies DC markers (70). Histamine 
actively participates in functions and activity of DC precursors as well as their 
immature and mature forms (Figure 1). Immature and mature DCs express all four 
HR, however comparison of their levels of expression has not yet been studied. In 
the differentiation process of DC1 from monocytes, HR1 and HR3 act as positive 
stimulants that increase antigen-presentation capacity and proinflammatory cytokine 
production and Th1 priming activity. In contrast, HR2 acts as a suppressive molecule 
for antigen-presentation capacity, enhances IL-10 production and induces IL-10-
producing T cells or Th2 cells (Table 2) (71)(72).  
In monocytes stimulated with Toll-like receptor-triggering bacterial products 
histamine inhibits the production of pro-inflammatory IL-1-like activity, TNFα, IL-12 
and IL-18, but enhances IL-10 secretion, through HR2 stimulation (26) (72). 
Histamine also downregulates CD14 expression via H2 receptors on human 
monocytes (73). The inhibitory effect of histamine via H2-receptor appears through 
the regulation of ICAM-1 and B7.1 expression, leading to the reduction of innate 
immune response stimulated by LPS (74). 
Histamine induces intracellular Ca++ flux, actin polymerization, and chemotaxis 
in immature DCs due to stimulation of HR1 and HR3 subtypes. Maturation of DCs 
results in loss of these responses. In maturing DCs, however, histamine dose-
dependently enhances intracellular cAMP levels and stimulates IL-10 secretion, while 
inhibiting production of IL-12 via HR2 (16). Interestingly, although human monocyte-
derived dendritic cells (MoDC) have both histamine H1 and H2 receptors and can 
induce CD86 expression by histamine, human epidermal Langerhans cells express 
neither H1 nor H2 receptors (75). 
 
Effect of histamine on T cells and antibody isotypes 
Histamine has been shown to intervene in the Th1, Th2, Treg cell balance and 
consequently antibody formation. Differential patterns of histamine receptor 
expression on Th1 and Th2 cells determine reciprocal T cell responses following 
histamine stimulation (Table 2) (Figure 1) (76). Th1 cells show predominant, but not 
exclusive expression of HR1, while Th2 cells show increased expression of HR2. 
Histamine enhances Th1-type responses by triggering the HR1, whereas both Th1- 
and Th2-type responses are negatively regulated by HR2, due to activation of 
different biochemical intracellular signals (76). In mice, deletion of HR1 results in 
suppression of IFN-γ and dominant secretion of Th2 cytokines (IL-4 and IL-13). HR2-
deleted mice show upregulation of both Th1 and Th2 cytokines. Bphs a non-major 
histocompatibility complex-linked gene involved in the susceptibility to many 
autoimmune diseases has been identified as HR1 gene in mice. HR1-deleted mice 
showed delayed disease onset and decreased disease severity when immunized to 
develop experimental allergic encephalomyelitis (77). It has also been shown that 
histamine stimulation induced IL-10 secretion through HR2 (1, 2). Increased IL-10 
production in both DC and T cells may account for an important regulatory 
mechanism in the control of inflammatory functions through histamine. Various 
cytokines regulate the production of histamine and its receptor expression. IL-3 
stimulation significantly increases HR1 expression on Th1, but not on Th2 cells (76).  
In mice, histamine enhances anti-IgMinduced proliferation of B cells, which is 
abolished in HR1-deleted mice. In HR1-deleted mice, antibody production against a 
T cell-independent antigen-TNP-Ficoll is decreased(15), suggesting an important role 
of HR1 signaling in responses triggered from B cell receptors. Antibody responses to 
T cell-dependent antigens like ovalbumin (OVA) show a different pattern (15). HR1-
deleted mice produced high OVA-specific IgG1 and IgE in comparison to wild type 
mice. In contrast, HR2-deleted mice showed decreased serum levels of OVA-specific 
IgE in comparison to wild type mice and HR1-deficient mice. Although T cells of HR2-
deficient mice secreted increased IL-4 and IL-13, OVA-specific IgE was suppressed 
in the presence of highly increased IFN-γ. Thus, HR1 and related Th1 response may 
play a dominant role in the suppression of humoral immune response. 
 
The role of histamine and H1 antihistamines during allergen-SIT 
The rationale for the use of H1-antihistamines during SIT is diverse and may 
include both the reduction of side effects, which may develop immediately after the 
shots of vaccine and providing help in the long term induction of allergen tolerance 
induced by vaccination. Pretreatment with antihistamines has been proposed as 
early as in 1980s as the effective approach to reduce the side effects of allergen 
immunotherapy (78) It has been confirmed in a number of studies that administration 
of high doses of second generation H1R antihistamines before vaccine shots of 
insect venom or grass pollen is effective in reduction of local allergic reactions and 
generalized symptoms of the urticaria and angioedema type (79-81). Unfortunately, 
this modality is much less effective in the reduction of more severe systemic 
symptoms (79-81). 
The effect of pre-treatment with terfenadine on the long-term protection from 
honeybee stings during rush immunotherapy with honeybee venom was analyzed in 
a double-blind, placebo-controlled trial (82). After an average of 3 years, 41 patients 
were re-exposed to honeybee stings. Surprisingly, none of 20 patients, who had 
been given HR1-antihistamine premedication, but 6 of 21 given placebo, had a 
systemic allergic reaction to the re-exposure by either a field sting or a sting 
challenge. This highly significant difference suggests that H1-antihistamine 
premedication during the initial dose-increase phase may have enhanced the long-
term efficacy of immunotherapy. This indicates a positive role of histamine in immune 
regulation during SIT (83). Similarly in the ETAC (early treatment of the atopic child) 
study - a double-blind placebo-controlled trial aiming at the determination of the 
preventative effect of cetirizine on the development of asthma which included 830 
children with atopic dermatitis aged 12–24 months it has been shown that treatment 
with cetirizine reduced relative risk of developing asthma for the children sensitized to 
grass pollen or house dust mite (84). These findings indicate the immunoregulatory 
and anti-inflammatory effects of H1 antihistamines. The underlying mechanisms are 
not fully elucidated. On one side treatment with H1R antagonists also results in H2R 
predominance. Moreover the expression of HR1 on T lymphocytes is strongly 
reduced during ultra rush immunotherapy, which may lead to a dominant expression 
of HR2. 
Peripheral T cell tolerance characterized by immune deviation to 
regulatory/suppressor T cells represents a key event in the control of specific immune 
response during allergen-specific immunotherapy (85). Although, multiple suppressor 
factors including contact dependent or independent mechanisms might be involved, 
IL-10 and TGF-β predominantly produced by allergen-specific T cells play an 
essential role (86, 87). Histamine interferes with the peripheral tolerance induced 
during SIT in several pathways. Histamine induces the production of IL-10 by 
dendritic cells (88). In addition, histamine induces IL-10 production by Th2 cells (89). 
Furthermore, histamine enhances the suppressive activity of TGF-β on T cells (90). 
All three of these effects are mediated via HR2, which is relatively highly expressed 
on Th2 cells and suppresses IL-4 and IL-13 production and T cell proliferation . 
Apparently, these recent findings suggest that HR2 may represent an essential 
receptor that participates in peripheral tolerance or active suppression of 
inflammatory/immune responses. Although the selective activation of H2R might be a 
more promising approach as compared to the use of H1 antihistamines, so far it has 
not been investigated in vivo.  
However, selective HR2 antagonists, have attracted interest because of their 
potential immune response-modifying activity (91). Most data suggest that cimetidine 
has a stimulatory effect on the immune system, possibly by blocking the receptors on 
subsets of T-lymphocytes and inhibiting HR2-induced immune suppression. 
Cimetidine has also been used successfully to restore immune functions in patients 
with malignant disorders, hypogammaglobulinemia and AIDS-related complexes.  
 
The use of H1 antihistamines in asthma 
Histamine administered intravenously or by inhalation causes 
bronchoconstriction, which is inhibited by HR1 antihistamines. Individuals with 
asthma are more sensitive to the bronchoconstrictor effect of histamine than healthy 
individuals are. Although current evidence does not support the use of H1-
antihistamines in persistent asthma, some investigators have shown a significant 
decrease in asthma symptoms and improvement in pulmonary function after H1-
antihistamine treatment (3, 92-95). Treatment with the H1-antihistamine cetirizine 
over a period of 18 months was reported to delay the onset of asthma in some young 
children with atopic dermatitis who were at high risk for the disease, however, this 
observation requires confirmation (3, 92-95). In sensitized mice, treatment with the 
H1-antihistamine fexofenadine before allergen challenge prevented airway 
hyperresponsiveness. Decreases in bronchoalveolar lavage fluid and tissue 
eosinophilia, lymphocyte numbers, and TH2 cytokine production were also observed 
in this model (96). Another HR1 antihistamine, desloratadine, given at the time of 
allergen exposure, inhibited the induction of allergic inflammation in the airways and 
bronchial hyperresponsiveness (97).  
Histamine-induced, concentration-dependent release of IL-6 and β-
glucuronidase from macrophages isolated from human lung parenchyma can be 
consistently inhibited by fexofenadine but not by ranitidine, an H2-antihistamine (98). 
Thus, long-term treatment with HR1 antihistamines might potentially alter disease 
progression in patients with respiratory allergy associated with tissue 
damage/remodeling mediated by macrophage and Th2 cell activation. 
Although previous studies suggested a basal tone of smooth muscle mediated 
by histamine binding to HR1, constitutive intrinsic activity of the HR1 without any 
occupation by histamine might be more relevant. Histamine also induces proliferation 
of cultured airway smooth muscle cells (66).  
Species differences in the response to histamine have been reported. HR2-
mediated bronchodilation occurs in cats, rats, rabbits, sheep and horses (67); 
however, in healthy and asthmatic humans, H2-antihistamines such as cimetidine and 
ranitidine do not cause bronchoconstriction (99, 100). Although there is no direct 
evidence that it plays a role in disease pathogenesis, HR2-mediated gastric secretion 
may be impaired in asthma (101). H2-antihistamines, given for the treatment of 
gastroesophageal reflux, improve asthma symptoms (102); whether this is an indirect 
effect due to down-regulation of gastric acid secretion, or whether it is a direct effect 
remains to be elucidated. In addition, recent studies suggest that histamine may play 
an important role in the modulation of the cytokine network in the lung via HR2, HR3 
and HR4 that are expressed in distinct cells and cell subsets (103, 104). Apparently, 
due to the same signal transduction patterns, β2 adrenergic receptors may function 
similar to HR2 in humans (105). Future research should focus on the role of 
histamine and other redundant G-protein-coupled receptors in the regulation of 
immune/inflammatory pathways in the lung.  
In particular, the discovery of a fourth histamine receptor (H4) and its 
expression on numerous immune and inflammatory cells has prompted a re-
evaluation of the actions of histamine, suggesting a new potential for H4-receptor 
antagonists and a possible synergy between H1 and H4-receptor antagonists in 
targeting various inflammatory conditions (106). 
 
Conclusions 
The emerging pattern of immune regulation by histamine is very complex and 
calls for further investigation. Histamine and 4 different histamine receptors constitute 
a multifaceted system with distinct functions of receptor types due to their differential 
expression, which changes according to the stage of cell differentiation and 
influences of the microenvironment. The diverse effects of histamine on immune 
regulation appear to be due to differential expression and regulation of 4 types of 
histamine receptors and their distinct intracellular signals. In addition, differences in 
affinities of these receptors for histamine is highly decisive for the biological effects of 
histamine and drugs that target histamine receptors. The cells involved in the 
regulation of immune response and hematopoiesis express histamine receptors and 
also secrete histamine. Histamine can selectively recruit the major effector cells into 
tissue sites and affect their maturation, activation, polarization, and other functions 
leading to chronic inflammation. Histamine also regulates dendritic cells, T cells and 
B cells, as well as related antibody isotype responses. Although contrasting findings 
have been reported, HR1 stimulates the immune system cells by potentiating their 
proinflammatory activity for increased migration to the area of inflammation as well as 
increased effector functions. In addition, acting through its receptor 2, histamine 
positively interferes with the peripheral antigen tolerance induced by T regulatory 
cells in several pathways. The data on the role of HR3 and HR4 in immune regulation 
are limited. The observation that H4R activation promotes the accumulation of 
inflammatory cells at sites of allergic inflammation opens a new window of 
therapeutic opportunity based on concurrent H1-antihistamine and H4-antihistamine 
administration, or development of selective dual H1-/H4-antihistamines. Whether such 
treatment will provide additional suppression of allergic inflammatory responses 
compared with that observed after H1-antihistamine treatment alone remains to be 
elucidated.  
 
 Table 1. Histamine receptors, expression, activated intracellular signals, and 
coupled G proteins. 
Histamine 
receptors 
Expression Activated intracellular signals G 
proteins 
Histamine 
H1 receptor 
nerve cells, airway and vascular smooth 
muscles, hepatocytes, chondrocytes, 
endothelial cells, epithelial cells, 
neutrophils, eosinophils, monocytes,  
DC, T and B cells 
 
Ca+2, cGMP, phospholipase D, 
phospholipase A2, 
NFκB 
Gq/11 
Histamine 
H2 receptor 
nerve cells, airway and vascular smooth 
muscles, hepatocytes, chondrocytes, 
endothelial cells, epithelial cells,  
neutrophils, eosinophils, monocytes,  
DC, T and B cells,  
 
 
adenylate cyclase,  
cAMP, c-Fos, c-Jun,  
PKC, p70S6K 
 
Gαs 
 
Histamine 
H3 receptor 
histaminergic neurons, eosinophils,  
DC, monocytes 
low expression in peripheral tissues 
 
enhanced Ca+2,  
MAP kinase,  
inhibition of cAMP 
 
Gi/o 
Histamine 
H4 receptor 
High expression on bone marrow and 
peripheral hematopoietic cells,  
eosinophils, neutrophils,   
DC, T cells, basophils, mast cells,  
low expression in nerve cells, hepatocytes 
peripheral tissues, spleen, thymus, lung, 
small intestine, colon and heart 
Enhanced Ca+2,  
Inhibition of cAMP, 
 
Gi/o 
 
  
 
Table 2. Histamine receptors in allergic inflammation and immune modulation  
 histamine H1 
receptor  
 
histamine H2 
receptor  
histamine H3 
receptor  
histamine H4 
receptor  
 
Histamine 
function  
in allergic  
inflammation  
and immune 
modulation 
 
increases release of 
histamine and other 
mediators;  
increases cellular adhesion 
molecule expression and 
chemotaxis of eosinophils 
and neutrophils; 
increases antigen-
presenting cell capacity, 
co-stimulatory activity on B 
cells; 
increases cellular immunity 
(Th1),  IFN-γ, auto-
immunity. 
decreases humoral 
immunity and  
IgE production. 
 
 
decreases eosinophil 
and neutrophil 
chemotaxis;  
decreases IL-12 by 
dendritic cells; 
increases IL-10 and 
induces development of 
Th2 or tolerance-
inducing dendritic cells:  
increases humoral 
immunity; decreases 
cellular immunity; 
suppresses Th2 cells 
and cytokines;  
role in allergy, auto-
immunity, malignancy, 
graft rejection  
 
probably involved in 
control of neurogenic 
inflammation through 
local neuron-mast cell 
feedback loops;  
increases pro-
inflammatory activity 
and APC capacity  
 
increases calcium 
flux in human 
eosinophils;  
increases eosinophil 
chemotaxis;  
increases IL-16 
production  
(H2-receptor also 
involved) 
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Legend to the figure 
 
 
Figure 1  
Histamine regulates monocyte, dendritic cell, T cells and B cell functions. Monocytes 
and dendritic cells express all four HRs. Activation of HR1 and HR3 triggers proinflammatory 
eventsand increases APC capacity.  HR2 plays a suppressive role on monocytes and 
monocyte-derived dendritic cells (DC). Th1 cells show predominant, but not exclusive, 
expression of HR1, whereas Th2 cells show upregulation of HR2. Histamine induces 
increased proliferation and IFN-γ production in Th1 cells. Th2 cells express predominant 
HR2, which acts as the negative regulator of proliferation, IL-4 and IL-13 production. 
Histamine enhances Th1-type responses by triggering the HR1, whereas both Th1- and 
Th2-type responses are negatively regulated by HR2, showing an essential role for immune 
regulation for this receptor. Distinct effects of histamine suggest roles of HR1 and HR2 on T 
cells for autoimmunity and peripheral tolerance, respectively. Histamine also modulates 
antibody production. Histamine directly effects B cell antibody production as a co-stimulatory 
receptor on B cells. HR1 predominantly expressed on Th1 cells may block humoral immune 
responses by enhancing Th1 type cytokine IFN-γ. In contrast, HR2 enhances humoral 
immune responses. Allergen-specific IgE production is differentially regulated in HR1- and 
HR2-deficient mice. HR1-deleted mice show increased allergen-specific IgE production, 
whereas HR2-deleted mice show suppressed IgE production. 
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Th1 cells: 
HR1 enhances IFN-γ 
production  
and Th1 cell 
proliferation,  
HR2 antagonizes 
this effect 
HR2 suppresses IL-4 and IL-
13 production and Th2 cell 
proliferation 
Histamine enhances  
the production of IL-10  
and the suppressive effect  
of TGF-β is potentiated via HR2  
Dendritic cells: 
HR1 increases antigen-presenting capacity and Th1 priming. HR2 
induces IL-10 production, suppresses antigen-presentation and 
aids development of IL-10-secreting T cells 
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HR1 blocks humoral immunity, induces cellular immunity  
HR2 blocks cellular immunity 
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HR2-deficient mice show suppressed specific IgE 
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